Exposure to a bacterial toxin called colibactin in early life is the leading suspect behind the doubling of early-onset bowel cancer cases in young people.
Patients with high-risk bowel cancer remained free of recurrence for nearly three years after receiving immunotherapy before surgery, according to the NEOPRISM-CRC trial.